The British company Destiny Pharma presented a compelling interim results of phase IIb studies of its experimental antibiotics, XF-73. During testing, the drug proved safe for human consumption, says PharmaTimes.
Destiny Pharma specializiruetsya on the creation of new options for treating nosocomial infections, which would help patients in the spread of drug resistance microorganisms. Platform XF allows to obtain compounds that destroy certain bacteria, including resistant strains.
In the current multicenter randomized blind placebo-controlled study evaluated the efficacy of an experimental drug in the prevention of postoperative bacterial infections including Staphylococcal aureus. Independent monitoring Board data, analyzing the collected the first 75 patients who had undergone surgical intervention on the heart, concluded that the safety of the medicine.
The study is expected to be completed by the end of 2020.